TINELLI, Martina
 Distribuzione geografica
Continente #
NA - Nord America 600
EU - Europa 553
AS - Asia 190
AF - Africa 2
OC - Oceania 2
SA - Sud America 2
Totale 1.349
Nazione #
US - Stati Uniti d'America 593
GB - Regno Unito 237
CN - Cina 158
IE - Irlanda 58
IT - Italia 58
SE - Svezia 55
FR - Francia 48
DE - Germania 36
FI - Finlandia 33
VN - Vietnam 13
BE - Belgio 12
UA - Ucraina 10
CA - Canada 7
TR - Turchia 6
KR - Corea 5
IR - Iran 3
AU - Australia 2
EG - Egitto 2
ES - Italia 2
JP - Giappone 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BG - Bulgaria 1
BR - Brasile 1
DK - Danimarca 1
IN - India 1
NL - Olanda 1
PL - Polonia 1
UZ - Uzbekistan 1
Totale 1.349
Città #
Southend 221
Chandler 120
Jacksonville 85
Ann Arbor 72
Woodbridge 63
Dublin 58
Beijing 36
New York 29
Houston 28
Ashburn 27
Verona 22
Jinan 17
Lawrence 14
Princeton 14
Helsinki 13
Brussels 12
Hebei 12
Wilmington 12
Shenyang 10
Nanchang 8
Nanjing 8
Dong Ket 7
Düsseldorf 7
Redmond 7
Cagliari 6
Changsha 6
Châtenay-Malabry 6
Haikou 6
Jiaxing 6
Hangzhou 5
Paris 5
Taiyuan 5
Tianjin 5
Bologna 4
Guangzhou 4
Ningbo 4
Redwood City 4
Renton 4
Seoul 4
Verdun 4
Zhengzhou 4
Dearborn 3
Fuzhou 3
Los Angeles 3
Montreal 3
Seattle 3
Sindelfingen 3
Auburn Hills 2
Boardman 2
Chicago 2
Fairfield 2
Lancaster 2
Lanzhou 2
Mit Ghamr 2
Montigny-le-Bretonneux 2
Norwalk 2
Nürnberg 2
Rovereto 2
Taizhou 2
Tokyo 2
Ardabil 1
Bangalore 1
Brisbane 1
Buenos Aires 1
Böblingen 1
Chaoyang 1
Chinon 1
Colorno 1
Costa Mesa 1
Dongguan 1
Hongtong 1
Kent 1
Leawood 1
Macomer 1
Madrid 1
Milan 1
Modesto 1
Monmouth Junction 1
Montgomery 1
Olgiate Molgora 1
Padova 1
Palermo 1
Rome 1
San Mateo 1
Shenzhen 1
Simi Valley 1
Sofia 1
Sydney 1
Tashkent 1
Warsaw 1
Washington 1
Whittier 1
Wuhan 1
Zanjan 1
Totale 1.062
Nome #
Interferon-alpha-engineered Multipotent Mesenchymal Stromal Cells for the treatment of myeloma 158
Endothelin B Receptor (Etbr) expression by human malignant plasma cells: preliminary evidence for a role of the endothelin axis in multiple myeloma. 123
Study of the efficacy of new drugs in a mouse model of multiple myeloma 114
Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. 107
Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia 101
Homing and Efficacy Assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmocytoma model 95
Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus 92
Efficacy assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model 91
Clinical, serologic and instrumental data of ten patients affected by sclerodermatous chronic graft versus host disease: similarities and differences in respect to systemic sclerosis 90
Interferon-alpha-engineered Multipotent Mesenchymal Stromal Cells for the treatment of myeloma 85
In Vitro and In Vivo Model of EBV-Positive Non-Hodgkin Plasmablastic Lymphoma with Focal Plasmacytic Differentiation 84
Bortezomib-induced muscle toxicity in multiple myeloma 75
In reply to Schäfer et al: new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma 73
null 55
IDENTIFICATION AND CHARACTERIZATION OF CANDIDATE MYELOID DERIVED SUP- PRESSOR CELLS IN THE MONONUCLEAR FRACTION OF PERIPHERAL BLOOD SAMPLES FROM PATIENTS AFFECTED BY NON-HODGKIN LYMPHOMA (NHL), HODGKIN LYMPHOMA (HL), AND MULTIPLE MYELOMA (MM) 35
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group 1
Totale 1.379
Categoria #
all - tutte 3.603
article - articoli 2.040
book - libri 0
conference - conferenze 1.302
curatela - curatele 0
other - altro 261
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.206


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201913 0 0 0 0 0 0 0 0 0 0 4 9
2019/2020164 15 2 5 10 15 34 11 13 6 14 15 24
2020/2021151 14 16 11 16 19 16 3 8 9 3 21 15
2021/2022137 17 37 1 14 12 2 3 6 5 5 11 24
2022/2023323 17 38 20 55 24 96 0 16 37 4 10 6
2023/2024147 5 8 10 18 16 41 10 17 0 13 9 0
Totale 1.379